SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 72 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2019 | $133,000 | +17.7% | 25,344 | 0.0% | 0.00% | – |
Q4 2018 | $113,000 | -72.4% | 25,344 | -50.0% | 0.00% | – |
Q3 2018 | $410,000 | +129.1% | 50,688 | +98.2% | 0.00% | – |
Q2 2018 | $179,000 | -50.8% | 25,568 | 0.0% | 0.00% | – |
Q1 2018 | $364,000 | +130.4% | 25,568 | +41.9% | 0.00% | – |
Q4 2017 | $158,000 | -12.7% | 18,016 | +16.6% | 0.00% | – |
Q3 2017 | $181,000 | -16.2% | 15,451 | 0.0% | 0.00% | – |
Q2 2017 | $216,000 | +113.9% | 15,451 | +109.9% | 0.00% | – |
Q1 2017 | $101,000 | +90.6% | 7,360 | 0.0% | 0.00% | – |
Q4 2016 | $53,000 | -28.4% | 7,360 | +49.9% | 0.00% | – |
Q3 2016 | $74,000 | +54.2% | 4,911 | 0.0% | 0.00% | – |
Q2 2016 | $48,000 | – | 4,911 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Kynam Capital Management, LP | 1,932,800 | $33,592,000 | 10.90% |
Aisling Capital Management LP | 1,025,000 | $17,815,000 | 9.61% |
Frazier Life Sciences Management, L.P. | 3,195,403 | $55,536,000 | 4.73% |
Paradigm Biocapital Advisors LP | 701,356 | $12,190,000 | 3.22% |
SPHERA FUNDS MANAGEMENT LTD. | 1,277,413 | $22,201,000 | 3.14% |
Nantahala Capital Management | 2,692,303 | $46,792,000 | 2.07% |
Avidity Partners Management LP | 4,823,400 | $83,831,000 | 1.75% |
DAFNA Capital Management LLC | 371,987 | $6,465,000 | 1.68% |
ACUTA CAPITAL PARTNERS, LLC | 206,126 | $3,582,000 | 1.67% |
BVF INC/IL | 2,394,714 | $41,620,000 | 1.66% |